Supplied strictly for in vitro laboratory research. Not for human consumption.

Retatrutide (development code LY3437943) is a synthetic peptide that has drawn significant attention in metabolic research as the first “triple agonist” to reach late-stage clinical study. Developed by Eli Lilly, it acts on three receptors at once — GLP-1, GIP, and glucagon. This guide explains what retatrutide is, how its mechanism works, and what the published research shows, written for research context only.

What is retatrutide?

Retatrutide is a single-molecule triple receptor agonist: it activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. It is a synthetic peptide developed by Eli Lilly and is the most advanced triple agonist in clinical development, currently studied in Phase 3 trials for obesity and type 2 diabetes.

Where earlier incretin compounds act on one or two of these receptors, retatrutide is notable for engaging all three in one molecule — which is the basis of the scientific interest in it.

Mechanism of action

Each of retatrutide’s three targets contributes a distinct effect:

GLP-1 receptor — the most-studied pathway in this class, associated with insulin secretion and appetite/satiety signalling.
GIP receptor — a second incretin pathway that also influences insulin response.
Glucagon receptor — the distinguishing addition. Glucagon agonism is associated with increased hepatic glucose output and energy expenditure through thermogenic pathways.

In isolation, glucagon agonism would tend to raise blood glucose. The mechanistic rationale behind retatrutide is that the insulinotropic action of GLP-1 and GIP counterbalances glucagon’s glycemic effect while preserving the increase in metabolic rate. This balance across three pathways is what researchers describe as mechanistically distinct from single- and dual-agonist compounds.

What the published research shows

The following is drawn from peer-reviewed clinical literature and is presented for research context only.

In a 48-week Phase 2 obesity trial published in the New England Journal of Medicine, retatrutide was associated with mean body-weight reductions of roughly 22.8% and 24.2% at the 8 mg and 12 mg doses — among the largest reductions reported for compounds in this class.

A Phase 2a substudy published in Nature Medicine examined participants with metabolic dysfunction-associated steatotic liver disease and reported relative liver-fat reductions of up to roughly 82% at higher doses over the study period.

In type 2 diabetes research, published Phase 2 data reported weight reductions around 16.9% at 36 weeks alongside improvements in HbA1c.

Retatrutide has since progressed to Phase 3 clinical trials. As an investigational compound, it is not approved for therapeutic use in any jurisdiction.

How retatrutide compares to other incretin peptides

Retatrutide is often discussed alongside two earlier compounds:

Semaglutide — a GLP-1 receptor mono-agonist.
Tirzepatide — a GIP/GLP-1 dual agonist.

Retatrutide’s addition of glucagon receptor activity to the GIP/GLP-1 combination is what defines it as a triple agonist, and is the variable researchers are most interested in when comparing the three.

Research and sourcing considerations

For laboratory research, the quality of the reference material matters as much as the compound itself. Reproducible results depend on verified identity and purity, which is why research-grade retatrutide should be supplied with:

Independent HPLC purity testing (≥99% purity), and
A batch-specific certificate of analysis (COA) confirming the identity and purity of the specific vial supplied.

DXB Peptides supplies research-grade retatrutide for in vitro laboratory use — HPLC-tested to ≥99% purity with a batch-specific COA, cold-chain handled and delivered across the UAE.

Frequently asked questions

What does retatrutide do? In published research, retatrutide is studied as a triple agonist acting on the GLP-1, GIP, and glucagon receptors — pathways involved in metabolic regulation.

Is retatrutide approved? No. It is an investigational compound in Phase 3 clinical trials and is not approved for therapeutic use.

What’s the difference between retatrutide and tirzepatide? Tirzepatide is a GIP/GLP-1 dual agonist; retatrutide adds glucagon receptor activity, making it a triple agonist.

What purity should research-grade retatrutide be? Look for independent HPLC testing at ≥99% purity, accompanied by a batch-specific certificate of analysis.

Important note

Retatrutide is supplied strictly for in vitro laboratory research. It is not a medicine, is not approved for human use in any jurisdiction, and is not for human consumption or in vivo administration.

Explore the full catalogue: Research peptides UAE

What Is Retatrutide? Mechanism & Research Overview